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T h e  effect o f  meth ionine  on the uptake,  distr ibution,  and binding of  the  
convulsan t  meth ionine  sulfoximine (MSO) in 7 rat brain regions,  the spinal cord,  
the liver, and the  kidney was investigated.  The  adminis t ra t ion o f  meth ionine  
decreased  the  uptake o f  M S O in all brain regions.  The  uptake  o f  M S O  by and its 
distr ibution in the  nervous  t issue was uni form and failed to result  in any  
preferential  accumula t ion  of  the  drug. Methionine  decreased  the amoun t  o f  
MSO bound  to cerebra l  s t ructures  and to the  spinal cord. MSO bound to the  
spinal cord was less susceptible to release by Tri ton X-100 than was bra in-bound 
MSO.  
I N T R O D U C T I O N  
For several years, various approaches have been used in an attempt to 
elucidate the mechanism of action of  the convulsant L-methionine-dl- 
sulfoximine (MSO). These have included studies on the effect of MSO 
on the cerebral metabolism of amino acids and ammonia (1-8), brain 
amines (9, 10), glycogen (7, 11), protein (12-14), and cerebral ultrastruc- 
ture (8, 15, 16). The antagonism of MSO seizures by methionine is also 
well documented (3, 17, 18). There is evidence for methionine antago- 
nism of the effect of  MSO on "bound" acetylcholine production in rat 
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T A B L E  I 
THE EFFECT OF PERFUSION ON TISSUE 
RADIOACTIVITY LEVELS ~ 
dpm/g 
Tissue Buffer + MSO Buffer Only 
Brain 36,550 36,866 
Spinal Cord 27,150 26,460 
Liver 179,250 164,969 
Kidney 298,950 278,315 
[aH]MSO was injected 3 hr prior to sacrifice. The total 
radioactivity values are means obtained from 2 (buffer 
+ MSO) and 4 (buffer only) animals. For perfusion 
details, see Experimental Procedure. 
cortical slices (19), rat brain S-adenosyl-L-methionine levels (20), mouse 
cerebellar ammonia (7), and rat brain glutamine synthetase (3). MSO 
and methionine have also been shown to be uptake antagonists (21, 22). 
We have investigated the effect of methionine on the uptake, distribu- 
tion and binding of [3H]MSO in 7 brain regions, the spinal cord, the 
liver, and the kidney of the adult rat. We also attempted to establish 
whether methionine antagonizes MSO by disallowing MSO to reach its 
nervous tissue targets in sufficiently high amounts to elicit seizures. 
EXPERIMENTAL PROCEDURE 
Animals and Drug Treatment. Adult male Sprague-Dawley rats weighing 100-160 g 
were used throughout the study. A mixture of nonradioactive (Sigma Chemical Co., St. 
Louis, Missouri) and radioactive MSO (0.94 mmol/kg) was administered intraperitoneally 
alone or jointly with L-methionine (4.7 mmol/kg) (ICN Biochemicals, Cleveland, Ohio) in 
a total volume of 10 ml/kg in saline. The animals were sacrificed 1, 3, or 6 hr later, i.e., 
well before (1 and 3 hr) the onset of the seizure, or immediately preceding it (6 hr). 
Purification of [3H]MSO. Methyl tritiated MSO (5.1 mCi/mmol), purified as previously 
described (23), was chromatographer on cellulose thin-layer-chromatography (TLC) plates 
(EM Laboratories, Elmsford, New York) in n-butanol, glacial acetic acid, and water 
(2:1:1), where it migrated identically with authentic nonradioactive MS O. Its final specific 
radioactivity was 3.67 mCi/mmol. Solutions of [aH]MSO were diluted for injection with 
nonradioactive MSO to achieve specific radioactivities of about 0.4 mCi/mmol. 
Preparation of Tissue. To minimize the contribution of circulating [3H]MSO to the 
estimation of the tissue radioactivity, animals were perfused immediately prior to sacrifice 
with either ice-cold 0.1 M sodium phosphate buffer, pH 7.4, or buffer containing 17 rag/ 
liter of nonradioactive MSO. As shown in Table I, identical results were achieved, 
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indicating that the presence of MS9 in the perfusing medium had no effect on the 
measurement of the tissue stores of [3H]MSO. Per-fusion was for 5 rain, i.e., until the 
perfusate was totally discolored. After perfusion, the brains were removed and dissected 
(24) into cerebellum (CL), brainstem (BS), striatum (ST), hypothalamus (HY), midbrain 
(MB), hippocampus (HI), and cerebral cortex (CX). The spinal cord, liver, and kidneys 
were also removed and, along with the brain regions, were weighed and homogenized in 10 
vol of ice-cold 0.32 M sucrose. The homogenates were centrifuged at 100,000 g for 70 rain. 
The resulting pellet was washed with an equal volume of  sucrose and the suspension was 
centrifuged as above yielding the "sucrose supernatant."  The washed "sucrose pellet" 
was homogenized in an equal volume of Triton X-100 (0.02%) (w/v) (Sigma Chemical Co.) 
and was centrifuged as above yielding a "Tri ton supernatant" and a "Tri ton pellet" which 
was homogenized in ice-cold deionized water. 
Determination of Radioactivity. Afiqnots of the whole homogenate, the "sucrose 
supernatant,"  the "Tri ton supernatant," and of the final "Tri ton pellet" suspension were 
digested in I ml of 2 N NaOH at 65~ for 16 hr. Samples were neutralized with 0.2 m][ of 
12 N HC1, and 10 ml PCS (Amersham Searle, Arlington Heights, Illinois) was added for 
determination of radioactivity. 
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The effect of methionine on the regional uptake of [3H]MSO in rat brain. 9 _-: 
[*H]MSO; 0 - - - - - -0  [3H]MSO + methionine. For dosages, see Experimental Procedure. 
Each point is the mean -+ SEM obtained from the number of animals indicated by the 
numeral in parentheses in CX, which is the same for all regions. The values represent 
pmoles of [~H]MSO/mg of protein in the regional homogenate. Open circles, 9 9 
denote a significant difference at the 0.05 level (see Experimental Procedure) from rats 
receiving only [3H]MSO. MB: midbrain; HI: hippocampus; CX: cortex; CL: cerebellum; 
BS: brainstem; ST: striatum; HY: hypothalamus. 
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Statistical Analyses. Statistical comparison of MSO vs. MSO + methionine-treated 
groups was done using the two-tailed Student's t test. 
RESULTS 
Uptake of [3H]MSO by Tissues 
There  were  no significant differences be tween M S O  and MSO + 
methionine-treated rats in any of the brain regions at 1 hr (Figure 1). At 
3 hr, the midbrain, the cerebellum, and the hypothalamus of animals 
receiving MSO + methionine contained significantly less [3H]MSO than 
was found in animals receiving MSO alone. At 6 hr [ZH]MSO levels in 
all brain regions, except the hippocampus, were lower than at 3 hr. The 
levels of [ZH]MSO were highest in the cerebellum at 3 hr (about 800 
pmol/mg of protein) (Figure 1) while in all other brain regions they failed 
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H O U R S  AFTER DRUG TREATMENT 
FIG. 2. The effect of methionine on the uptake of [~H]MSO by whole brain, spinal cord, 
liver, and kidney. 9 9  [3H]MSO; 9  9  [3H]MSO + metbionine. For dosages, see 
Experimental Procedure. Each point is the mean - SEM obtained from the number of 
animals indicated by the numeral in parentheses in kidney which is the same for all organs. 
The values represent pmoles or nmoles of [3H]MSO/mg of protein in the organ homoge- 
nate. Open circles, O 9 denote a significant difference at the 0.05 level (see 
Experimental Procedure) from rats receiving only [ZH]MSO. 
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FIG. 3. Effect of methionine on the regional distribution of MS9 in rat brain. 9 ~ :  
[3H]MSO; Q O:  [3H]MSO + methionine. For dosages, see Experimental Procedure. 
For abbreviations, see legend to Figure 1. Each point represents the mean -+ SEM 
obtained from the number of animals indicated by the numeral in parentheses in CX, 
which is the same for all regions. The values refer to [3H]MSO present in the region as a 
percent of the radioactivity in the whole brain homogenate. As in Figure 1, open circles, 
9 9 denote a significant difference at the 0.05 level (see Experimental Procedure) 
from rats receiving only [3H]MSO. Note difference in y-axis scales between CX and all 
other regions. 
significantly reduced by the administration of methionine, particularly in 
the spinal cord and the peripheral organs (Figure 2). This methionine- 
induced decrease became significant in the whole brain only at 6 hr 
(Figure 2). The levels of [~H]MSO in the spinal cord reached the 
cerebellar values by 3 hr and thus exceeded those of any other brain 
region. During the 6-hr experimental period the levels of [nil]MS9 in 
the peripheral organs decreased from 10 to 4 nmol/mg of protein in the 
kidney and from 4 to 2 nmot/mg of protein in the liver (Figure 2). 
Regional Distribution of [ZH]MSO in Rat Brain 
Only the cortex showed a sharp increase in its share of the total tissue 
[3H]MSO between 1 and 3 hr; in all other regions the 3 hr values were 
not apparently different from those at 1 hr. One hour after the adminis- 
tration of [3H]MSO + methionine, there was less [ZH]MSO in all brain 
regions, except in the cortex and the striatum, than in the corresponding 
regions of animals which received [3H]MSO only (Figure 3). At 3 hr, 
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except for the hippocampus which contained a greater share of the total 
[aH]MSO in animals receiving [3H]MSO + methionine than in those 
receiving [3H]MSO alone, there was no significant difference in the 
percentages of [3H]MSO between the two groups of animals. Finally, at 
6 hr a higher percentage of the total [3H]MSO was found in the 
hippocampus, the cerebellum, and the hypothalamus of animals receiv- 
ing [3H]MSO + methionine than in those receiving [aH]MSO only; 
conversely a lower percentage was found in the cortex of animals 
receiving [3H]MSO + methionine than was present in those receiving 
[3H]MSO only. 
Effect of Methionine on [3H]MSO Binding 
"Bound"  [3H]MSO is defined in this paper as the [3H]MSO re- 
covered in the "sucrose pellet" (see Experimental Procedure). The 
amount of bound [3H]MSO was calculated by combining the values 
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FIG. 4. The effect of methionine on the regional binding of [3H]MSO in rat brain. r e: 
[aH]MSO; O------O: [~H]MSO • methionine. For dosages, see Experimental Procedure. 
For abbreviations, see the legend to Figure 1. Each point represents the mean • SEM 
obtained from the number of animals indicated by the numeral in parentheses in CX, 
which is the same for all regions. The values refer to [aH]MSO recovered in the washed 
"sucrose pellet" (see Experimental Procedure) as percent of the radioactivity present in 
the regional homogenate. As in Figures 1 and 3, open circles, 9 9 denote a significant 
difference at the 0.05 level (see Experimental Procedure) from rats receiving only 
[3H]MSO, 
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expressed as the percentage of the total [3H]MSO in the tissue homoge- 
nate. At 1 hr, only the cerebellum and the cortex contained any bound 
[~H]MSO (Figure 4). Highest values of bound [3H]MSO were found in 
the hippocampus at 6 hr and in the cortex at 3 hr (about 9%). A notable 
finding, shown in Figure 4 as well as in Table II, was that methionine 
greatly reduced the binding of [3H]MSO in all brain regions. This finding 
could be confirmed when bound [3H]MSO determinations were per- 
formed on samples of whole brain (data not shown). 
Effect of  Triton X-IO0 on MSO Release 
Triton X-I00 homogenization (see Experimental Procedure) released 
all of the bound [3H]MSO (Table II) at 1 hr, while at 3 and 6 hr this 
treatment proved effective only in releasing [3H]MSO bound in the 
absence of methionine. The small amounts of [3H]MSO bound when 
methionine was coadministered (Figure 4) became resistant to Triton 
except in the cerebellum, where 32% of the tissue-bound [3H]MSO was 
released. Triton X-100 also effectively released [3H]MSO bound in the 
peripheral organs, although this process appeared to diminish in inten- 
sity with time (Table III)i 
D I S C U S S I O N  
The concurrent administration of [aH]MSO + methionine resulted, 
within 3-6 hr, in general and significant reductions of [3H]MSO uptake 
by all brain regions except the hippocampus (Figure 1). This finding 
extends our previous observation (22) which dealt with the cortex and 
the cerebellum only, to 5 additional brain regions. Furthermore, as 
shown in Figure 2, significantly less [3H]MSO was present in the spinal 
cord, the liver, and the kidney of animals receiving the combination of 
[3H]MSO + methionine than in those receiving only [3H]MSO. This 
protective effect of methionine became apparent as early as 1 hr 
postadministration and lasted throughout the entire preconvulsant pe- 
riod. 
The accumulation of [~H]MSO in the brain regions (Figure 3) was, in 
general, directly proportional to their weights. There was, however, a 
shift in the regional partition of [aH]MSO with time, as evidenced by its 
marked increase, between 1 and 3 hr, in the cortex and its parallel 
decrease in the cerebellum, the midbrain, the brainstem, and the 
hippocampus. It is of particular interest that the administration of 
methionine altered the time course of the regional partition of [3H]MSO 
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TABLE III  
THE EFFECT OF TRITON X-100 ON RELEASE OF [3H]MSO IN RAT ORGANS AFTER 
TREATMENT WITH MSO OR MSO + METHIONINE a 
Rat organ 
Hours after 
treatment N Treatment Brain Spinal cord Liver Kidney 
l 3 MSO 100 (8) 100 (227) 100 (579) 96 (669) 
2 MSO + - -  100 (27) 78 (122) 100 (688) 
methionine 
3 5 MSO 79 (148) 100 (105) 71 (158) 94 (726) 
3 MSO + 14 (4) - -  0 (37) 87 (320) 
metbionine 
6 3 MSO 81 (90) 44 (63) 40 (102) 39 (369) 
MSO + 0 (2) - -  60 (35) 0 (15) 
methionine 
a Values refer to % of [3H]MSO released by 0.02% Triton. Values in parentheses are 
pmol/mg of protein of [3H]MSO bound and represent 100%. Dashed lines signify absence 
of any [aH]MSO binding. For drug schedule and description of binding experiments see 
Experimental Procedure. N = number of animals. 
for, under these conditions, the drug reached high cortical levels at 1 hr, 
but, by 3 hr, appeared to decay and accumulate instead in the cerebel- 
lum and the hippocampus.  
Although quantitatively much inferior, the binding of  [3H]MSO in 
brain appeared tighter when the drug was given with methionine (Tables 
I I  and l iD,  rather than alone, a phenomenon briefly noted before (22). 
An increase in Triton-resistant [3H]MSO binding in the peripheral 
organs with time was also noted, and this occurred after administering 
[3H]MSO by itself and with methionine (Table I I I ) .  [35S]MSO binding in 
mouse brain and liver was previously reported by Rao and Meister (26) 
who identified the presumably protein-bound radioactivity as MSO 
phosphate.  We have heretofore failed to demonstrate  soluble MSO 
metabolites in rat brain (22, 25). Moreover,  more recently we conducted 
a number of chromatographic experiments using a variety of  organ 
extracts of  [3H]MSO-treated rats and uncovered no evidence for the 
existence of  soluble [3H]MSO metabolites. 
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